International Assets Investment Management LLC Makes New $61,000 Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

International Assets Investment Management LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 149 shares of the company’s stock, valued at approximately $61,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Rise Advisors LLC bought a new stake in Medpace in the first quarter valued at $27,000. Mather Group LLC. acquired a new stake in shares of Medpace in the 1st quarter valued at about $28,000. Fidelis Capital Partners LLC bought a new stake in Medpace in the 1st quarter valued at about $31,000. J.Safra Asset Management Corp raised its stake in Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after buying an additional 47 shares during the period. Finally, DT Investment Partners LLC bought a new position in Medpace in the second quarter worth approximately $41,000. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $347.10 on Thursday. Medpace Holdings, Inc. has a fifty-two week low of $227.21 and a fifty-two week high of $459.77. The company’s 50-day moving average is $394.94 and its 200 day moving average is $396.39. The company has a market capitalization of $10.75 billion, a P/E ratio of 35.38, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, beating analysts’ consensus estimates of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The firm had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same period in the prior year, the firm earned $1.93 EPS. The company’s revenue was up 14.6% compared to the same quarter last year. As a group, research analysts predict that Medpace Holdings, Inc. will post 11.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on MEDP. StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research report on Friday, August 9th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, July 23rd. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research report on Wednesday, July 24th. Guggenheim dropped their price target on shares of Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research report on Wednesday, July 24th. Finally, Mizuho started coverage on Medpace in a report on Tuesday, May 28th. They set a “buy” rating and a $435.00 price objective for the company. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $423.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.